Efficacy and safety of 4 months of sublingual immunotherapy with recombinantMal d 1 and Bet v 1 in patients with birch pollen-related apple allergy

摘要

Background: Birch pollen-related apple allergy is among the most prevalent food allergies in adolescent/adult subjects and mainly results from sensitization to the major birch pollen allergen Bet v 1 and subsequent cross-reaction with the apple protein Mal d 1. However, specific immunotherapy with birch pollen has inconsistent effects on apple allergy.